{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:03:26Z","timestamp":1778778206310,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG3K0291"],"award-info":[{"award-number":["CORPG3K0291"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007404","name":"Clinical Trial Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Linkou Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-TDU-B-212-124005"],"award-info":[{"award-number":["MOHW110-TDU-B-212-124005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mortality rates due to Cryptococcus neoformans var. grubii fungemia remain significant despite treatment with antifungal drugs. The predictive function of antifungal susceptibility and its correlation with treatment outcome remains controversial. A retrospective study was conducted from January 1, 2009, to December 31, 2016, on 85 patients with C. neoformans var. grubii fungemia confirmed by matrix-assisted laser desorption ionization\u2013time-of-flight mass spectrometry. Antifungal drug susceptibility was determined using the YeastONE\u2122 colorimetric broth microdilution method coupled with Vizion\u2122 System following the Clinical and Laboratory Standards Institute guidelines. Six antifungal agents\u2014amphotericin B, fluconazole, flucytosine, itraconazole, posaconazole, and voriconazole\u2014were tested. The patients\u2019 demographic data and clinical information were abstracted for further analyses. Antifungal regimens consisting of amphotericin B with or without fluconazole or flucytosine were administered for induction treatment of these patients, followed with intravenous or oral fluconazole for maintenance therapy. Clinical outcomes were defined by 14- and 30-day mortality rates. Risk factors associated with outcomes were fitted in a logistic regression model by univariate or multivariate method. Eighty-five patients with C. neoformans var. grubii fungemia were enrolled in the study. The Sequential Organ Failure Assessment Score, Glasgow Coma Scale, Charlson comorbidity score, and adequate duration of therapy for amphotericin B were predictors for mortality in univariate analysis. Antifungal susceptibility testing with YeastONE\u2122 does not predict clinical outcomes of C. neoformans var. grubii fungemia. Greater disease severity, high comorbidities, poor consciousness level, and inappropriate treatment were associated with increased mortality in cryptococcemia cases.<\/jats:p>","DOI":"10.1093\/mmy\/myab046","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T11:16:06Z","timestamp":1628248566000},"page":"1114-1121","source":"Crossref","is-referenced-by-count":8,"title":["Antifungal susceptibility testing with YeastONE\u2122 is not predictive of clinical outcomes of <i>Cryptococcus neoformans<\/i> var. <i>grubii<\/i> fungemia"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7814-4723","authenticated-orcid":false,"given":"Jeng-How","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung), New Taipei City 23652, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Yen","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City 33305, Taiwan"},{"name":"Infection Control Committee, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Wen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shian-Sen","family":"Shie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Fu","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung), New Taipei City 23652, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Biostatistics Unit of Clinical Trial Center, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Unit of Clinical Trial Center, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-3432","authenticated-orcid":false,"given":"Ting-Shu","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City 33305, Taiwan"},{"name":"Infection Control Committee, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"2021110223542411300_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis."},{"key":"2021110223542411300_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1469-0691.12360","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"2021110223542411300_bib3","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1128\/AAC.00034-11","article-title":"Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome","volume":"55","author":"Larsen","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223542411300_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12879-015-1023-8","article-title":"Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Infect Dis."},{"key":"2021110223542411300_bib5","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002\u20132003 and 2007\u20132008","volume":"55","author":"Govender","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223542411300_bib6","doi-asserted-by":"crossref","first-page":"ofw076","DOI":"10.1093\/ofid\/ofw076","article-title":"Retrospective study of cryptococcal meningitis with elevated minimum inhibitory concentration to fluconazole in immunocompromised patients","volume":"3","author":"Nasri","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"2021110223542411300_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/JCM.01747-08","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol."},{"key":"2021110223542411300_bib8","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.01520-05","article-title":"Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis","volume":"50","author":"Dannaoui","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223542411300_bib9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of fluconazole MICs with clinical outcome in cryptococcal infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223542411300_bib10","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts","author":"CLSI","year":"2017","edition":"4th ed"},{"key":"2021110223542411300_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jac\/42.4.439","article-title":"Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans","volume":"42","author":"Davey","year":"1998","journal-title":"J Antimicrob Chemother."},{"key":"2021110223542411300_bib12","volume-title":"Epidemiological Cutoff Values for Antifungal Susceptibility Testing","year":"2020","edition":"3rd ed"},{"key":"2021110223542411300_bib13","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1128\/JCM.00651-11","article-title":"Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry","volume":"49","author":"McTaggart","year":"2011","journal-title":"J Clin Microbiol."},{"key":"2021110223542411300_bib14","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.3314\/mmj.16-00002","article-title":"Identification of Disseminated Cryptococcosis Using MALDI-TOF MS and Clinical Evaluation","volume":"57","author":"Tarumoto","year":"2016","journal-title":"Med Mycol J."},{"key":"2021110223542411300_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","article-title":"Cryptococcosis","volume":"30","author":"Maziarz","year":"2016","journal-title":"Infect Dis Clin North Am."},{"key":"2021110223542411300_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005792-198303000-00003","article-title":"Cryptococcemia","volume":"62","author":"Perfect","year":"1983","journal-title":"Medicine (Baltimore)."},{"key":"2021110223542411300_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.md.0000126760.45299.69","article-title":"Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates","volume":"83","author":"Singh","year":"2004","journal-title":"Medicine (Baltimore)."},{"key":"2021110223542411300_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/clinids\/22.2.322","article-title":"Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing","volume":"22","author":"Witt","year":"1996","journal-title":"Clin Infect Dis."},{"key":"2021110223542411300_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/JCM.37.3.591-595.1999","article-title":"Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms","volume":"37","author":"Espinel-Ingroff","year":"1999","journal-title":"J Clin Microbiol."},{"key":"2021110223542411300_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1439-0507.2004.01013.x","article-title":"Comparative evaluation of Sensititre YeastOne vs. the NCCLS M27A protocol and E-test for antifungal susceptibility testing of yeasts","volume":"47","author":"Lombardi","year":"2004","journal-title":"Mycoses."},{"key":"2021110223542411300_bib21","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol."},{"key":"2021110223542411300_bib22","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/JCM.36.10.2817-2822.1998","article-title":"Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies","volume":"36","author":"Lozano-Chiu","year":"1998","journal-title":"J Clin Microbiol."},{"key":"2021110223542411300_bib23","first-page":"143","article-title":"Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent","volume":"21","author":"Pasqualotto","year":"2004","journal-title":"Rev Iberoam Micol."}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myab046\/40075991\/myab046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/11\/1114\/40811062\/myab046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/11\/1114\/40811062\/myab046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:54:42Z","timestamp":1635897282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/59\/11\/1114\/6347351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myab046","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,8,10]]}}}